HUALAN BIOLOGICAL VACCINE INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.22 CNY | -7.63% |
|
-8.84% | -27.27% |
| Apr. 25 | Hualan Biological Vaccine Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Apr. 01 | Hualan Biological Vaccine Inc. Proposes Final Cash Dividend for 2023 | CI |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 17,832 | 16,680 | 12,102 | - | - |
| Enterprise Value (EV) 1 | 17,832 | 16,680 | 12,102 | 12,102 | 12,102 |
| P/E ratio | 33.7 x | 19.5 x | 11.7 x | 9.68 x | 7.47 x |
| Yield | - | 2.16% | 3.52% | 4.16% | 5.4% |
| Capitalization / Revenue | 9.77 x | 6.92 x | 4.13 x | 3.49 x | 2.82 x |
| EV / Revenue | 9.77 x | 6.92 x | 4.13 x | 3.49 x | 2.82 x |
| EV / EBITDA | 24.3 x | 14.4 x | 9.13 x | 7.69 x | 5.99 x |
| EV / FCF | - | 20,206,055 x | - | - | - |
| FCF Yield | - | 0% | - | - | - |
| Price to Book | 3.24 x | 2.66 x | 1.71 x | 1.51 x | 1.26 x |
| Nbr of stocks (in thousands) | 600,015 | 600,015 | 600,015 | - | - |
| Reference price 2 | 29.72 | 27.80 | 20.17 | 20.17 | 20.17 |
| Announcement Date | 3/29/23 | 3/29/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | 1,830 | 1,826 | 2,410 | 2,932 | 3,466 | 4,290 |
| EBITDA 1 | - | 733.2 | 1,155 | 1,326 | 1,574 | 2,020 |
| EBIT 1 | - | 592.6 | 1,010 | 1,215 | 1,466 | 1,900 |
| Operating Margin | - | 32.46% | 41.9% | 41.46% | 42.3% | 44.28% |
| Earnings before Tax (EBT) 1 | - | 589.5 | 1,007 | 1,214 | 1,464 | 1,897 |
| Net income 1 | - | 519.6 | 860 | 1,036 | 1,250 | 1,620 |
| Net margin | - | 28.46% | 35.68% | 35.34% | 36.08% | 37.78% |
| EPS 2 | 1.150 | 0.8807 | 1.428 | 1.730 | 2.083 | 2.700 |
| Free Cash Flow | - | - | 825.5 | - | - | - |
| FCF margin | - | - | 34.25% | - | - | - |
| FCF Conversion (EBITDA) | - | - | 71.48% | - | - | - |
| FCF Conversion (Net income) | - | - | 95.99% | - | - | - |
| Dividend per Share 2 | - | - | 0.6000 | 0.7100 | 0.8400 | 1.090 |
| Announcement Date | 3/29/22 | 3/29/23 | 3/29/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | - | 826 | - | - | - |
| ROE (net income / shareholders' equity) | - | 10.6% | 14.7% | 14.9% | 15.8% | 16.9% |
| ROA (Net income/ Total Assets) | - | - | 11.4% | 12.1% | 13% | 15.1% |
| Assets 1 | - | - | 7,535 | 8,598 | 9,619 | 10,732 |
| Book Value Per Share 2 | - | 9.160 | 10.40 | 11.80 | 13.40 | 16.00 |
| Cash Flow per Share 2 | - | 0.4800 | 1.480 | 1.690 | 1.960 | 2.440 |
| Capex 1 | - | 92.3 | 62.5 | 171 | 110 | 165 |
| Capex / Sales | - | 5.06% | 2.59% | 5.83% | 3.19% | 3.85% |
| Announcement Date | 3/29/22 | 3/29/23 | 3/29/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
20.17
CNY
Average target price
29.3
CNY
Spread / Average Target
+45.27%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -27.27% | 1.68B | |
| -2.99% | 89.49B | |
| +2.50% | 40.67B | |
| -13.49% | 33.15B | |
| +62.42% | 26.45B | |
| -19.65% | 14.69B | |
| -7.92% | 12.89B | |
| -12.64% | 11.54B | |
| -43.92% | 11.34B | |
| +4.04% | 8.84B |
- Stock Market
- Equities
- 301207 Stock
- Financials Hualan Biological Vaccine Inc.
